NO20043418L - Stabiliserte adenovirusformuleringer - Google Patents
Stabiliserte adenovirusformuleringerInfo
- Publication number
- NO20043418L NO20043418L NO20043418A NO20043418A NO20043418L NO 20043418 L NO20043418 L NO 20043418L NO 20043418 A NO20043418 A NO 20043418A NO 20043418 A NO20043418 A NO 20043418A NO 20043418 L NO20043418 L NO 20043418L
- Authority
- NO
- Norway
- Prior art keywords
- adenovirus formulations
- stabilized
- stabilized adenovirus
- formulations
- adenovirus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34922202P | 2002-01-18 | 2002-01-18 | |
| PCT/US2003/001055 WO2003061708A1 (en) | 2002-01-18 | 2003-01-15 | Stabilized formulations of adenovirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20043418L true NO20043418L (no) | 2004-08-17 |
Family
ID=27613260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043418A NO20043418L (no) | 2002-01-18 | 2004-08-17 | Stabiliserte adenovirusformuleringer |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20030232018A1 (no) |
| EP (1) | EP1465664A1 (no) |
| JP (1) | JP2005515245A (no) |
| KR (1) | KR20040077878A (no) |
| CN (1) | CN1617745A (no) |
| AR (1) | AR038153A1 (no) |
| BR (1) | BR0306925A (no) |
| CA (1) | CA2469721A1 (no) |
| IL (1) | IL162404A0 (no) |
| MX (1) | MXPA04006995A (no) |
| NO (1) | NO20043418L (no) |
| PE (1) | PE20030851A1 (no) |
| PL (1) | PL371261A1 (no) |
| RU (1) | RU2004125283A (no) |
| TW (1) | TW200307750A (no) |
| UY (1) | UY27614A1 (no) |
| WO (1) | WO2003061708A1 (no) |
| ZA (1) | ZA200406547B (no) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103118702A (zh) | 2010-09-20 | 2013-05-22 | 克鲁塞尔荷兰公司 | 活动性结核病的治疗性接种 |
| CA2809463C (en) | 2010-09-27 | 2021-05-25 | Crucell Holland B.V. | Heterologous prime boost vaccination regimen against malaria |
| US9044498B2 (en) | 2010-12-02 | 2015-06-02 | Oncolytics Biotech Inc. | Lyophilized viral formulations |
| TW201233802A (en) | 2010-12-02 | 2012-08-16 | Oncolytics Biotech Inc | Liquid viral formulations |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| PL2825640T3 (pl) | 2012-03-12 | 2016-10-31 | Partie rekombinowanych adenowirusów o zmienionych końcach | |
| CA2867950C (en) | 2012-03-22 | 2023-02-21 | Crucell Holland B.V. | Vaccine against rsv |
| US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
| WO2014174018A1 (en) | 2013-04-25 | 2014-10-30 | Crucell Holland B.V. | Stabilized soluble prefusion rsv f polypeptides |
| CA2914792C (en) | 2013-06-17 | 2024-02-27 | Crucell Holland B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
| PL3283634T3 (pl) | 2015-04-14 | 2019-10-31 | Janssen Vaccines & Prevention Bv | Rekombinowany adenowirus eksprymujący dwa transgeny z dwukierunkowym promotorem |
| EP3319634B1 (en) | 2015-07-07 | 2019-08-21 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
| AU2016289492B2 (en) | 2015-07-07 | 2022-08-11 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
| US20180280519A1 (en) * | 2015-10-06 | 2018-10-04 | Janssen Vaccines & Prevention B.V. | Methods for preventing plastic-induced degradation of biologicals |
| KR102500970B1 (ko) | 2016-04-05 | 2023-02-17 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv에 대한 백신 |
| HUE053027T2 (hu) | 2016-04-05 | 2021-06-28 | Janssen Vaccines & Prevention Bv | Stabilizált, szolúbilis prefúziós RSV F fehérje, RSV-fertõzés megelõzésében történõ alkalmazásra |
| BR112018072865A2 (pt) | 2016-05-12 | 2019-04-30 | Janssen Vaccines & Prevention B.V. | promotor bidirecional potente e equilibrado |
| DK3464331T3 (da) | 2016-05-30 | 2021-01-18 | Janssen Vaccines & Prevention Bv | Stabiliserede præfusions-rsv f-proteiner |
| BR112018075969A2 (pt) | 2016-06-20 | 2019-04-02 | Janssen Vaccines & Prevention B.V. | promotor bidirecional potente e equilibrado |
| EP3484506A1 (en) | 2016-07-14 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Hpv vaccines |
| KR102111244B1 (ko) | 2017-02-09 | 2020-05-15 | 얀센 백신스 앤드 프리벤션 비.브이. | 이종 유전자의 발현을 위한 강력한 짧은 프로모터 |
| WO2018210871A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| EP3624844A1 (en) | 2017-05-17 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| SG11202001458SA (en) | 2017-09-15 | 2020-03-30 | Janssen Vaccines & Prevention Bv | Method for the safe induction of immunity against rsv |
| TW202204380A (zh) | 2020-01-31 | 2022-02-01 | 美商詹森藥物公司 | 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗 |
| WO2022175477A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ287157B6 (en) * | 1993-07-13 | 2000-10-11 | Rhone Poulenc Rorer Sa | Defective recombinant adenovirus and pharmaceutical preparation in which said adenovirus is comprised |
| FR2718150B1 (fr) * | 1994-03-29 | 1996-04-26 | Rhone Poulenc Rorer Sa | Virus recombinants, préparation et utilisation en thérapie génique. |
| JP2000514290A (ja) * | 1996-07-01 | 2000-10-31 | ローヌ―プーラン・ロレ・エス・アー | 組換えアデノウイルスの製造方法 |
| FR2751343B1 (fr) * | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
| US6544769B1 (en) * | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
| KR100918187B1 (ko) * | 1998-02-17 | 2009-09-22 | 쉐링 코포레이션 | 바이러스를 포함하는 조성물 및 바이러스 제제의 농축방법 |
| US6689600B1 (en) * | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| EP1150712B1 (en) * | 1999-02-05 | 2008-11-05 | Merck & Co., Inc. | Human papilloma virus vaccine formulations |
| WO2001066137A1 (en) * | 2000-03-07 | 2001-09-13 | Merck & Co., Inc. | Adenovirus formulations |
-
2003
- 2003-01-15 CN CNA038023423A patent/CN1617745A/zh active Pending
- 2003-01-15 RU RU2004125283/15A patent/RU2004125283A/ru not_active Application Discontinuation
- 2003-01-15 WO PCT/US2003/001055 patent/WO2003061708A1/en not_active Application Discontinuation
- 2003-01-15 EP EP03731914A patent/EP1465664A1/en not_active Withdrawn
- 2003-01-15 KR KR10-2004-7011108A patent/KR20040077878A/ko not_active Application Discontinuation
- 2003-01-15 JP JP2003561650A patent/JP2005515245A/ja active Pending
- 2003-01-15 BR BR0306925-7A patent/BR0306925A/pt not_active Application Discontinuation
- 2003-01-15 AR ARP030100110A patent/AR038153A1/es unknown
- 2003-01-15 US US10/342,344 patent/US20030232018A1/en not_active Abandoned
- 2003-01-15 PL PL03371261A patent/PL371261A1/xx not_active Application Discontinuation
- 2003-01-15 CA CA002469721A patent/CA2469721A1/en not_active Abandoned
- 2003-01-15 MX MXPA04006995A patent/MXPA04006995A/es unknown
- 2003-01-15 IL IL16240403A patent/IL162404A0/xx unknown
- 2003-01-17 PE PE2003000051A patent/PE20030851A1/es not_active Application Discontinuation
- 2003-01-17 UY UY27614A patent/UY27614A1/es not_active Application Discontinuation
- 2003-01-17 TW TW092101013A patent/TW200307750A/zh unknown
-
2004
- 2004-08-17 NO NO20043418A patent/NO20043418L/no not_active Application Discontinuation
- 2004-08-17 ZA ZA200406547A patent/ZA200406547B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04006995A (es) | 2005-07-13 |
| WO2003061708A1 (en) | 2003-07-31 |
| RU2004125283A (ru) | 2005-06-10 |
| PE20030851A1 (es) | 2004-01-01 |
| JP2005515245A (ja) | 2005-05-26 |
| US20030232018A1 (en) | 2003-12-18 |
| PL371261A1 (en) | 2005-06-13 |
| UY27614A1 (es) | 2003-08-29 |
| IL162404A0 (en) | 2005-11-20 |
| CN1617745A (zh) | 2005-05-18 |
| ZA200406547B (en) | 2006-06-24 |
| TW200307750A (en) | 2003-12-16 |
| AR038153A1 (es) | 2004-12-29 |
| CA2469721A1 (en) | 2003-07-31 |
| EP1465664A1 (en) | 2004-10-13 |
| BR0306925A (pt) | 2004-11-09 |
| KR20040077878A (ko) | 2004-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20043418L (no) | Stabiliserte adenovirusformuleringer | |
| DK3536344T3 (da) | Superfin formoterolformulering | |
| DK1812025T3 (da) | Stabiliserede bakteriofagformuleringer | |
| IS8309A (is) | Lyfjablöndur | |
| PT1501534E (pt) | Formulacoes farmaceuticas | |
| NO20052635D0 (no) | Kontrollert frigivelsesdepot formuleringer | |
| FR2842417B1 (fr) | Composition cosmetique | |
| FR2842416B1 (fr) | Composition cosmetique | |
| DK3473251T3 (da) | Nikotin-cellulose-kombination | |
| NO20033556L (no) | Farmasöytiske formuleringer | |
| DE60231431D1 (de) | Ement | |
| DK1689360T3 (da) | Tørpulverformuleringer | |
| DK1421841T3 (da) | Mejetærsker | |
| DE60209252D1 (de) | Stabilisierte polymerzusammensetzung | |
| IS6915A (is) | Lyfjablanda | |
| DE10393374D2 (de) | Zusammensetzung | |
| BR0210619A (pt) | composição | |
| SE0500163L (sv) | Sammansättning | |
| DE60322720D1 (de) | Feste formulierungen enthaltend eine indolinon verbindung | |
| IS7081A (is) | Lyfjablanda | |
| DK1561472T3 (da) | Faststofsammensætning | |
| DK1539089T3 (da) | Reducerede aerosol-genererende formuleringer | |
| DE60218346D1 (de) | Stabilisierte topische brivudin-formulierungen | |
| IS7500A (is) | thurrdufts samsetningar | |
| ITMI20011532A0 (it) | Cosmetico solido |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |